Novavax Inc. (NVAX) 6.91 $NVAX
Interesting NVAX Put And Call Options For August 19th
DividendChannel.com - Tue Jun 21, 9:38AM CDT
Investors in Novavax, Inc. saw new options begin trading this week, for the August 19th expiration.
NVAX: 6.91 (+0.22)
Novavax Recognized by Washington Post as Top Workplace
GlobeNewswire - Fri Jun 17, 7:30AM CDT
Novavax, Inc. (Nasdaq:NVAX), today announced that, for the third consecutive year, it has been recognized as a Top Workplace for 2016.
NVAX: 6.91 (+0.22)
Novavax Has Returned 24.3% Since SmarTrend Recommendation (NVAX)
Comtex SmarTrend(R) - Fri Jun 17, 1:08AM CDT
SmarTrend identified an Uptrend for Novavax (NASDAQ:NVAX) on May 24th, 2016 at $5.45. In approximately 3 weeks, Novavax has returned 24.33% as of today's recent price of $6.77.
NVAX: 6.91 (+0.22)
Novavax Rises 2.81% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Jun 15, 3:05PM CDT
Novavax (NASDAQ:NVAX) traded in a range yesterday that spanned from a low of $6.59 to a high of $6.90. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $6.64 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NVAX: 6.91 (+0.22)
23.4% Return Seen to Date on SmarTrend Novavax Call (NVAX)
Comtex SmarTrend(R) - Thu Jun 09, 1:55PM CDT
SmarTrend identified an Uptrend for Novavax (NASDAQ:NVAX) on May 24th, 2016 at $5.45. In approximately 2 weeks, Novavax has returned 23.42% as of today's recent price of $6.72.
NVAX: 6.91 (+0.22)
Novavax Announces New Seasonal Combination Respiratory Vaccine Program
Globe Newswire - Thu Jun 02, 3:11PM CDT
- Seasonal influenza nanoparticle approach replaces VLP program
NVAX: 6.91 (+0.22)
Novavax Rises 6.66% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue May 31, 5:08PM CDT
Novavax (NASDAQ:NVAX) traded in a range yesterday that spanned from a low of $5.93 to a high of $6.29. Yesterday, the shares gained 6.7%, which took the trading range above the 3-day high of $6.06 on volume of 4.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NVAX: 6.91 (+0.22)
U.S. FDA Grants Fast Track Designation to Novavax' RSV F Vaccine for Older Adults
Globe Newswire - Wed May 25, 7:01AM CDT
GAITHERSBURG, Md., May 25, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Novavax' RSV F-Protein nanoparticle vaccine candidate (RSV F Vaccine) for the protection of older adults (60 years of age and older).
NVAX: 6.91 (+0.22)
After Yesterday's Rally of 2.48% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon May 23, 4:22PM CDT
Novavax (NASDAQ:NVAX) traded in a range yesterday that spanned from a low of $5.26 to a high of $5.47. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $5.31 on volume of 2.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NVAX: 6.91 (+0.22)
Novavax Receives the Tech Council of Maryland's Chairman's Award
Globe Newswire - Thu May 12, 7:30AM CDT
GAITHERSBURG, Md., May 12, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it received the Tech Council of Maryland's (TCM) Chairman's Award. The award was announced at the TCM Industry Award Celebration on May 11, 2016.
NVAX: 6.91 (+0.22)
Novavax to Participate in the 2016 Citi Midwest Healthcare Access Day
Globe Newswire - Wed May 11, 3:05PM CDT
GAITHERSBURG, Md., May 11, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced management will participate in the 2016 Citi Midwest Healthcare Access Day.
NVAX: 6.91 (+0.22)
Novavax reports 1Q loss
Automated Insights - Wed May 04, 5:30PM CDT
GAITHERSBURG, Md. (AP) _ Novavax Inc. (NVAX) on Wednesday reported a loss of $77.3 million in its first quarter.
NVAX: 6.91 (+0.22)
Novavax Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 3:05PM CDT
Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced its financial results for the first quarter ended March 31, 2016.
NVAX: 6.91 (+0.22)
Better Buy: Inovio Pharmaceuticals Inc. vs. Novavax Inc.
Keith Speights, The Motley Fool - Motley Fool - Tue May 03, 2:25PM CDT
Image Source: Inovio Pharmaceuticals Similarities only go so far. Inovio Pharmaceuticals and Novavax illustrate the point. Both are clinical-stage biotechs with hopes to win regulatory approval for vaccines in the relatively near future. Both...
INO: 9.85 (-0.35), NVAX: 6.91 (+0.22)
Interesting NVAX Put And Call Options For August 19th
DividendChannel.com - Tue Jun 21, 9:38AM CDT
Investors in Novavax, Inc. saw new options begin trading this week, for the August 19th expiration.
NVAX: 6.91 (+0.22)
Novavax Recognized by Washington Post as Top Workplace
GlobeNewswire - Fri Jun 17, 7:30AM CDT
Novavax, Inc. (Nasdaq:NVAX), today announced that, for the third consecutive year, it has been recognized as a Top Workplace for 2016.
NVAX: 6.91 (+0.22)
Novavax Has Returned 24.3% Since SmarTrend Recommendation (NVAX)
Comtex SmarTrend(R) - Fri Jun 17, 1:08AM CDT
SmarTrend identified an Uptrend for Novavax (NASDAQ:NVAX) on May 24th, 2016 at $5.45. In approximately 3 weeks, Novavax has returned 24.33% as of today's recent price of $6.77.
NVAX: 6.91 (+0.22)
Novavax Rises 2.81% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Jun 15, 3:05PM CDT
Novavax (NASDAQ:NVAX) traded in a range yesterday that spanned from a low of $6.59 to a high of $6.90. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $6.64 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NVAX: 6.91 (+0.22)
23.4% Return Seen to Date on SmarTrend Novavax Call (NVAX)
Comtex SmarTrend(R) - Thu Jun 09, 1:55PM CDT
SmarTrend identified an Uptrend for Novavax (NASDAQ:NVAX) on May 24th, 2016 at $5.45. In approximately 2 weeks, Novavax has returned 23.42% as of today's recent price of $6.72.
NVAX: 6.91 (+0.22)
Novavax Announces New Seasonal Combination Respiratory Vaccine Program
Globe Newswire - Thu Jun 02, 3:11PM CDT
- Seasonal influenza nanoparticle approach replaces VLP program
NVAX: 6.91 (+0.22)
Novavax Rises 6.66% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue May 31, 5:08PM CDT
Novavax (NASDAQ:NVAX) traded in a range yesterday that spanned from a low of $5.93 to a high of $6.29. Yesterday, the shares gained 6.7%, which took the trading range above the 3-day high of $6.06 on volume of 4.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NVAX: 6.91 (+0.22)
U.S. FDA Grants Fast Track Designation to Novavax' RSV F Vaccine for Older Adults
Globe Newswire - Wed May 25, 7:01AM CDT
GAITHERSBURG, Md., May 25, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Novavax' RSV F-Protein nanoparticle vaccine candidate (RSV F Vaccine) for the protection of older adults (60 years of age and older).
NVAX: 6.91 (+0.22)
After Yesterday's Rally of 2.48% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon May 23, 4:22PM CDT
Novavax (NASDAQ:NVAX) traded in a range yesterday that spanned from a low of $5.26 to a high of $5.47. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $5.31 on volume of 2.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NVAX: 6.91 (+0.22)
Novavax Receives the Tech Council of Maryland's Chairman's Award
Globe Newswire - Thu May 12, 7:30AM CDT
GAITHERSBURG, Md., May 12, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it received the Tech Council of Maryland's (TCM) Chairman's Award. The award was announced at the TCM Industry Award Celebration on May 11, 2016.
NVAX: 6.91 (+0.22)
Novavax to Participate in the 2016 Citi Midwest Healthcare Access Day
Globe Newswire - Wed May 11, 3:05PM CDT
GAITHERSBURG, Md., May 11, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced management will participate in the 2016 Citi Midwest Healthcare Access Day.
NVAX: 6.91 (+0.22)
Novavax reports 1Q loss
Automated Insights - Wed May 04, 5:30PM CDT
GAITHERSBURG, Md. (AP) _ Novavax Inc. (NVAX) on Wednesday reported a loss of $77.3 million in its first quarter.
NVAX: 6.91 (+0.22)
Novavax Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 3:05PM CDT
Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced its financial results for the first quarter ended March 31, 2016.
NVAX: 6.91 (+0.22)
Better Buy: Inovio Pharmaceuticals Inc. vs. Novavax Inc.
Keith Speights, The Motley Fool - Motley Fool - Tue May 03, 2:25PM CDT
Image Source: Inovio Pharmaceuticals Similarities only go so far. Inovio Pharmaceuticals and Novavax illustrate the point. Both are clinical-stage biotechs with hopes to win regulatory approval for vaccines in the relatively near future. Both...
INO: 9.85 (-0.35), NVAX: 6.91 (+0.22)
